Marino Garcia

Last Friday, shares of Synergy Pharmaceuticals Inc (NASDAQ: SGYP) traded down 5.78 percent, even though the company made public positive data from its first of two Phase III trials for its clinical constipation-predominant irritable bowel syndrome (IBS-C) drug, plecanatide. On Monday, research...